In 2025, our Carlsbad, California, site opened and became our third US site dedicated to manufacturing radioligand therapies (RLT). RLT is a type of precision treatment that pairs a tumor-targeting molecule (ligand) with a therapeutic radioisotope, allowing radiation to be delivered directly to the tumor while minimizing harm to surrounding healthy tissue.  

The Carlsbad site is built for further expansion to support current and future demand and ongoing innovation in RLT. 

Radioligand therapy manufacturing facility in Carlsbad, CA.

Key Facts About the Site

2025
site opened
10K
square-foot site 
1 of 5
US RLT manufacturing sites

See Photos from Our Carlsbad Site

See photos from our groundbreaking in Carlsbad, and our Novartis team members working on RLT production to deliver medicines to patients.
  • Novartis executives and dignitaries cut ribbon on Novartis RLT manufacturing facility in Carlsbad, California. View
    1/4
  • Attendees at the Carlsbad ribbon-cutting to celebrate the launch of the new site. View
    2/4
  • Novartis President, Operations Steffen Lang, Carlsbad Site Head Dominic Ramirez-Lopez, CEO Vas Narasimhan (left to right) at the site opening. View
    3/4
  • Carter Jaynes, RLT Production Manager at Novartis, who delivers doses of RLT to cancer patients. View
    4/4
scientists fist bumping

Explore Career Opportunities at Novartis

From science roles to manufacturing to business, find the right role at Novartis in the US and join us as we work to reimagine medicine.

Learn More

Featured Stories

Team shot at the groundbreaking, with shovels in sand.

Innovating for America: How Our New RLT Manufacturing Site Can Help Ensure Continued On Time Delivery to Patients Now and in Future

As Novartis expands its manufacturing capabilities, our new Carlsbad facility will help deliver time-sensitive cancer treatments to patients, meeting future demand.
2 2001 Aerial photo-d

Novartis in San Diego: A Quarter Century of R&D Innovation

A look back at a legacy of biomedical research breakthroughs that trace their roots to our San Diego site.
neuron imagen

What's next in Neuroscience drug discovery

A Q&A with Bryan Laffitte, who leads a Novartis team that’s using the tools of genetic medicine to innovate new therapies for neuromuscular and neurodegenerative conditions.

Latest News

Feb 25, 2026

  • Media Release

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Jan 09, 2026

  • Media Release

Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment

Nov 10, 2025

  • Media Release

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan
View More

See Our Other US Sites

Novartis Biomedical Research Center in San Diego, California

San Diego, CA

In 2026, we broke ground on a new global Biomedical Research center designed to accelerate drug discovery.
Novartis radioligand therapy site under construction in Indianapolis

Indianapolis, IN

Our second US radioligand therapy manufacturing site opened in 2024. Expansion of the site is ongoing.
Novartis Cell Therapy Production Morris Plains New Jersey

Morris Plains, NJ

Since 2015, the site has specialized in the production of groundbreaking cell therapies.
Novartis Gene Therapy Production, Durham, NC

Durham, NC (14TW)

Expected to be operational in 2028, the site will house two new facilities for manufacturing biologics and sterile packaging.
Novartis Gene Therapy Production Durham North Carolina

Durham, NC (TriCenter)

The site produces innovative gene therapies and is expanding to support sterile filling of biologics into syringes and vials. 
Morrisville, North Carolina

Morrisville, NC

Two new facilities for production and packaging of small molecule medicines, and active pharmaceutical ingredient manufacturing.
Novartis Radioligand Therapy Production Millburn New Jersey

Millburn, NJ

Our first US radioligand therapy manufacturing site opened in 2023. Its on-site production capabilities continue to expand.
Biomedical Research organization in Cambridge, Massachusetts

Cambridge, MA

This Biomedical Research organization, established in 2003, is dedicated to scientific innovation and drug discovery.
radioligand therapy manufacturing facility in Winter Park, Florida

Winter Park, FL

Expected to open in 2029, our fourth US radioligand manufacturing site will optimize delivery for patients across the southeastern US.
Scientist working in a laboratory with test tubes and scientific equipment

Denton, TX

Expected to become fully operational in 2028, our fifth US radioligand manufacturing site will serve patients in the southern US.

Learn More About Our Investment in the US

Return to Investing in America's Health